World Health Organization Raises Concern Over Acute Lack of Weight-Loss Medications

Fewer than 10% of individuals that would benefit from obesity jabs such as Wegovy have access to them, caution the WHO as it publishes its inaugural recommendations on the drugs.

With in excess of 1,000,000,000 individuals worldwide now living with obesity, it is advocating for broader and more equitable access to GLP-1 medication.

According to forecasts, in excess of 2,000,000,000 will be obese by 2030 if no action is taken.

"Our latest guidance affirms that obesity is a long-term condition that can be addressed with thorough and continuous support," stated its chief Tedros Adhanom Ghebreyesus.

High costs, constrained manufacturing, and supply-chain constraints are significant barriers to universal availability to the jabs that can help people shift significant body mass, notes the organization.

GLP-1 Therapy Shortage

Despite the current best projected case, the supply of such drugs might only reach about 100 million people – fewer than 10% of eligible patients, per the WHO.

The guideline encourages nations and manufacturers to expand access, by measures like patent sharing.

The intellectual property rights on a key compound – the primary component of a leading brand – is set to lapse in a number of nations in 2026.

The Way Weight-Loss Drugs Operate

GLP-1 drugs mimick a natural hormone to slow digestion, suppress the appetite and increase the sense of being full so individuals consume fewer calories.

Individuals usually see weight reduction within a few weeks of beginning the regular doses.

Evidence points to users may regain a significant portion within a year of halting the drug, because their typical hunger return.

Being carrying excess weight raises your risk for contracting medical conditions, like diabetes, cardiovascular issues, stroke, and specific malignancies.

Excess weight affects individuals in all nations and was responsible for 3.7 million deaths worldwide in 2024, per the WHO.